Loading...

PRTA PROTHENA CORP PUBLIC LTD CO Product Launches 8-K Filing

PRTH

PRT

PROTHENA CORP PUBLIC LTD CO

(PRTA)

2025 8-K

Show Summary

Show Summary

Management Changes

Product Expansion

Product Discontinuation

Financial Statements

Financial Results

Director Resignation

Q3 Financial Results

Management Change

Financial Results Announcement

Annual Meeting Approval

Earnings Reports

Appointment of Director

Earnings Release

Financial Update

Earnings Release

Earnings Release

Annual Meeting Approval

Appointment of Director

Earnings Release

Resignation of Director

Regulation FD Disclosure

Earnings Report

External Links:

On May 23, 2025, Prothena Corporation announced the results of its Phase 3 AFFIRM-AL trial for birtamimab, leading to the discontinuation of its development.

AI Assistant

PROTHENA CORP PUBLIC LTD CO

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.